mRNA Cocktail Erases Pancreatic Tumors in Half of Mice
A new mRNA-based immunotherapy has shown unprecedented success in animal models of pancreatic cancer. Researchers at UMass Chan Medical School developed a single injection combining five cytokine mRNAs and three tumor-associated antigens. In mice with pancreatic ductal adenocarcinoma, approximately 50% experienced complete tumor regression that lasted up to one year after treatment stopped. The therapy works by weakening the fibrotic barrier around tumors and training the immune system to recognize cancer cells, potentially creating long-term immune memory. While mouse results do not guarantee human success, the team is developing an IND-ready product for clinical trials.